“Stable Clear-Almost Clear Response Is Sustained up to 3 Years in Patients With Moderate-To-Severe Atopic Dermatitis Treated With Lebrikizumab”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s599, https://doi.org/10.25251/y4a30r91.